Displaying 181 (all) recruiting clinical trials.
-
A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
The purpose of the study is to evaluate the safety and efficacy of AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced ... -
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti PD-1) INCAGN02385 (Anti LAG-3) and INCAGN02390 (Anti TIM-3) in Participants With Select Advanced Malignancies
The purpose of the study is to determine safe combination doses and preliminary safety and efficacy for the combination of INCAGN02385, INCAGN02390, and INCMGA00012. INCMGA00012 ... -
A Phase 1 Open Label Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors
The purpose of the study is to determine the recommended Phase 2 dose of ORIN1001 when given as a single agent as well as phase ... -
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ... -
An Open-label Multicenter Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer
The purpose of the study is to determine the safety and antitumor activity of amivantamab delivered subcutaneously (SC) or under the skin with and without ... -
GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients
The purpose of the trial is to assess the safety and efficacy of the Gene Mediated Cytotoxic Immunotherapy (GMCI) added to standard of care immune ... -
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered Recurrent or Progressive Low-Grade Glioma
The purpose of the study is to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with ... -
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A
The purpose of the study is to evaluate the safety, efficacy and tolerability of one or more experimental arms for the treatment of advanced renal ... -
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B
The purpose of the study is to evaluate the safety, tolerability and efficacy of 1 or more experimental arms for the treatment of advanced renal ... -
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients with Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce ...